Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
February 08 2024 - 4:05PM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical & Sports Medicine markets, today announced that
fourth quarter and fiscal year 2023 financial results will be
reported after the market closes on Thursday, February 29th.
Management will host a conference call at 5:00
p.m. Eastern Time on February 29th to discuss the results of the
quarter and fiscal year, and provide a corporate update with a
question and answer session. Those who would like to participate
may access the live webcast here, or access the teleconference
here. The live webcast can also be accessed via the company’s
website at investors.organogenesis.com. The webcast will be
archived on the company website for approximately one year.
About Organogenesis Holdings
Inc. Organogenesis Holdings Inc. is a leading regenerative
medicine company focused on the development, manufacture and
commercialization of solutions for the advanced wound care and
surgical and sports medicine markets. Organogenesis offers a
comprehensive portfolio of innovative regenerative products to
address patient needs across the continuum of care. For more
information, visit www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Apr 2023 to Apr 2024